Clinical Trial Update: Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing NN1250 with insulin glargine plus insulin aspart, with/without metformin and with/without pioglitazone, in people with type 2 diabetes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• Insulin aspart (insulin aspart)
• NN1250

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-11-13